Welireg (belzutifan), an oral HIF-2 alpha inhibitor, has been approved by the FDA for adults with von Hippel-Lindau (VHL) disease ... neuroendocrine tumours (pNET). The FDA approval is based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback